Literature DB >> 10961965

Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina.

F Cipollone1, G Ciabattoni, P Patrignani, M Pasquale, D Di Gregorio, T Bucciarelli, G Davì, F Cuccurullo, C Patrono.   

Abstract

BACKGROUND: Unstable angina is associated with enhanced lipid peroxidation and reduced antioxidant defenses. We have previously reported aspirin failure in the suppression of enhanced thromboxane (TX) biosynthesis in a subset of episodes of platelet activation in this setting. We tested the hypothesis that the in vivo formation of the F(2)-isoprostane 8-iso-prostaglandin (PG)F(2alpha), a bioactive product of arachidonic acid peroxidation, is enhanced in unstable angina and contributes to aspirin-insensitive TX biosynthesis. METHODS AND
RESULTS: Urine samples were obtained from patients with unstable angina (n=32), stable angina (n=32), or variant angina (n=4) and from 40 healthy subjects for the measurement of immunoreactive 8-iso-PGF(2alpha) and 11-dehydro-TXB(2). 8-Iso-PGF(2alpha) excretion was significantly higher in patients with unstable angina (339+/-122 pg/mg creatinine) than in matched patients with stable angina (236+/-83 pg/mg creatinine, P:=0.001) and control subjects (192+/-71 pg/mg creatinine, P:<0.0001). In patients with unstable angina, 8-iso-PGF(2alpha) was linearly correlated with 11-dehydro-TXB(2) excretion (rho=0.721, P:<0.0001) and inversely correlated with plasma vitamin E (rho=-0.710, P:=0. 004). Spontaneous myocardial ischemia in patients with variant angina or ischemia elicited by a stress test in patients with stable angina was not accompanied by any change in 8-iso-PGF(2alpha) excretion, thus excluding a role of ischemia per se in the induction of increased F(2)-isoprostane production.
CONCLUSIONS: These findings establish a putative biochemical link between increased oxidant stress and aspirin-insensitive TX biosynthesis in patients with unstable angina and provide a rationale for dose-finding studies of antioxidants in this setting.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961965     DOI: 10.1161/01.cir.102.9.1007

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  40 in total

1.  Antioxidant supplementation reduces endometriosis-related pelvic pain in humans.

Authors:  Nalini Santanam; Nino Kavtaradze; Ana Murphy; Celia Dominguez; Sampath Parthasarathy
Journal:  Transl Res       Date:  2012-05-31       Impact factor: 7.012

Review 2.  Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements.

Authors:  Joseph M Sweeny; Diana A Gorog; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2009-04       Impact factor: 32.419

3.  Antiplatelet Effect of Sequential Administration of Cilostazol in Patients with Acetylsalycilic Acid Resistance.

Authors:  Muzaffer Cakmak; Bora Demircelik; Mustafa Cetin; Zehra Cetin; Serhat Isık; Hulya Cıcekcıoglu; Feridun Vasfi Ulusoy; Beyhan Eryonucu
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

4.  NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities.

Authors:  Heng-Lan Kuo; Jin-Cherng Lien; Ching-Hu Chung; Chien-Hsin Chang; Shyh-Chyi Lo; I-Chun Tsai; Hui-Chin Peng; Sheng-Chu Kuo; Tur-Fu Huang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-27       Impact factor: 3.000

Review 5.  Antiplatelet agents in hemodialysis.

Authors:  Massimiliano Migliori; Vincenzo Cantaluppi; Alessia Scatena; Vincenzo Panichi
Journal:  J Nephrol       Date:  2016-12-08       Impact factor: 3.902

6.  Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis.

Authors:  Pierre-François Lesault; Laurent Boyer; Gabriel Pelle; Ala Covali-Noroc; Dominique Rideau; Servais Akakpo; Emmanuel Teiger; Jean-Luc Dubois-Randé; Serge Adnot
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

7.  Platelets oxidative stress in Indian patients with ischemic heart disease.

Authors:  Mahdi Garelnabi; Vinod Gupta; Venkatesan Mallika; Jayashree Bhattacharjee
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

8.  Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation.

Authors:  Tae-Hyun Yang; Doo Il Kim; Jong Yoon Kim; Il Hwan Kim; Ki-Hun Kim; Yang Chun Han; Woong Kim; Sang Hoon Seol; Seong Man Kim; Dae Kyeong Kim; Dong Soo Kim
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

Review 9.  Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells.

Authors:  Giovanni Anfossi; Isabella Russo; Gabriella Doronzo; Alice Pomero; Mariella Trovati
Journal:  Mediators Inflamm       Date:  2010-06-28       Impact factor: 4.711

10.  Regulation of thromboxane receptor signaling at multiple levels by oxidative stress-induced stabilization, relocation and enhanced responsiveness.

Authors:  Stephen K Ball; Mark C Field; John R Tippins
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.